Patent Application
20250082603
The present invention relates to an ophthalmic composition containing recoflavone for the treatment of dry eye disease, which is a 3′,4′,5-trimethoxyflavone derivative compound and a method for preparing the same. Specifically, in order to maximize the improvement of symptoms of dry eye, the present invention relates to an ophthalmic composition containing a certain concentration of the active ingredient and at least one of permeation enhancers, and a method for preparing the same, so that the active ingredient, recoflavone, can sufficiently penetrate the cornea in vivo to exhibit significant therapeutic effects.
Dry eye disease is known as a disease that causes inflammation on an ocular surface and discomfort in eyes due to an increased osmolarity of the tear film and loss of tear homeostasis caused by tear deficiency or excessive tear evaporation. However, there was much controversy regarding the appropriate definition for dry eye until only a few years ago, the Tear Film and Ocular Surface Society (TFOS) defined dry eye disease as follows in 2017: “Dry eye disease is a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film, and accompanied by ocular symptoms, in which tear film instability, hyperosmolarity, inflammation and damage of ocular surface, and neurosensory abnormalities play etiological roles. (TFOS DEWS II introduction. Ocul. Surf. 2017, 15, 269-275).” The diagnosis of dry eye disease is performed by using such methods as questionnaires about symptoms, tear volume, tear film breakup time, tear osmolarity, keratoconjunctival staining and the analysis of lipid layer or meibomian gland, and depending on the degree of dry eye disease, artificial tears, anti-inflammatory agent, tear secretion promoters, autologous serum and eyelid treatment are used for the treatment (J. Korean Med. Assoc. 2018, 61(6), 352-364).
For the treatment of dry eye disease, tear replacement approaches with ocular lubricants such as artificial tears are most commonly used and typical examples thereof are eye drops containing sodium hyaluronate or sodium carboxymethylcellulose. For anti-inflammatory therapy, a cyclosporine formulation is used to reduce the immunoactivity markers (e.g., human leukocyte antigen-antigen D related), apoptosis markers (e.g., Fas) and inflammatory cytokines (e.g., interleukin-6) in keratoconjunctival epithelium to treat inflammation on the ocular surface and improve the symptoms of dry eye. The recently developed diquafosol (diquafosol tetrasodium) formulation is a P2Y2 receptor agonist and exhibits the promotion of secretion of aqueous and mucous components of tear. In Japan, a rebamipide suspension formulation has been proven to be effective in increasing the density of goblet cells in eyes and increasing the mucous and aqueous components of tear, and is used as a therapeutic agent for dry eye disease.
Recoflavone is a 3′,4′,5-trimethoxyflavone derivative compound, C20H18O8, and has a molecular weight of 386.4 by 2-((2-(3,4-dimethoxyphenyl)-5-methoxy-4-oxo-4H-chromen-7-yl)oxy) acetic acid.
Korea Patent Registrations Nos. 10-0447918, 10-0327621 and 10-0644928 disclosed the applicability of recoflavone to gastrointestinal diseases such as gastritis and gastric ulcer, and inflammatory bowel diseases such as Crohn's disease and colitis by the anti-inflammatory effect and the promotion of gastric mucus secretion. Korea Patent Registration No. 10-0930467 disclosed the conjunctival mucus secretion promoting action of 3′,4′,5-trimethoxyflavone derivative compounds including recoflavone and the applicability as an agent for treating and preventing dry eye disease.
Korea Patent Registration No. 10-0644928 described that recoflavone can be used in the form of an anhydride as it is, but since its hygroscopicity causes problems in handling and management, it can be improved when it is used as a hydrate.
Recoflavone is practically insoluble in water. It has a property with low solubility at low pH. As the pH increases, it is ionized and its solubility increases. However, even when it was dissolved, recoflavone exhibits poor cell permeability due to the high degree of ionization and it could have a problem in the absorption into the body. In fact, when a 3% eye drop was administered to rabbit eyes and the drug distribution in each tissue of eye with time was evaluated, the results showed that recoflavone was rarely distributed in the tissues located inside the eye and mainly distributed in the surrounding tissues outside of the eye, such as the cornea, conjunctiva, and sclera. In particular, the results showed that the drug concentration in the cornea was high immediately after the administration, but it was rapidly decreased over time and the drug was mainly distributed in the conjunctiva and sclera (data not shown).
Therefore, it needs that an eye drop formulation of recoflavone can penetrate the keratoconjunctiva in vivo in a certain amount or more and a method for preparing the same so that it can exhibit significant therapeutic effects on the overall symptoms of dry eye disease.
(Patent Document 1) Korea Patent Registration No. 10-0327621
(Patent Document 2) Korea Patent Registration No. 10-0447918
(Patent Document 3) Korea Patent Registration No. 10-0644928
(Patent Document 4) Korea Patent Registration No. 10-0930467
(Non-patent Document 1) TFOS DEWS II introduction. Ocul. Surf. 2017, 15, 269-275
(Non-patent Document 2) J. Korean Med. Assoc. 2018, 61(6), 352-364
(Non-patent Document 3) Invest. Ophthalmol. Vis. Sci., 2014, 55(10), 6569˜6574
(Non-patent Document 4) Cornea, 2017, 36(6), 712-718
(Non-patent Document 5) Br. J. Ophthalmol. 2010, 94, 1519˜1522
The present invention relates to an ophthalmic composition containing recoflavone for the treatment of dry eye disease, and provides an ophthalmic composition of which active ingredients can penetrate the keratoconjunctiva in vivo in a certain amount or more and a method for preparing the same so that recoflavone can exhibit significant therapeutic effects on the overall symptoms of dry eye disease.
Korea Patent Registration No. 10-0930467 disclosed that recoflavone showed some evidences for the treatment of dry eye disease, such as the promotion of mucus secretion, at a low drug concentration and had the possibility of development as a therapeutic agent of dry eye disease.
Normally, when a scar occurs in the keratoconjunctiva of an eye, the expression of major mucin proteins, such as MUC1, MUC4, MUC16, and MUC5AC, is increased. However, the patients with dry eye disease complain some discomfort because the mucus secretion is not good enough even though it is easy to get scars in their cornea. The pharmacological mucin secretion by recoflavone in human keratoconjunctival epithelial cells was studied and it confirmed that the thickness of the mucin layer was significantly increased when 100 μM solution of the active ingredient was applied. However, real-time Polymerase Chain Reaction (PCR) confirmed that the mucin proteins related with the symptoms of dry eye, which were MUC1, MUC4, MUC16 and MUC5AC, showed a tendency to increase significantly for four hours and then decreased rapidly. The Western blot analysis also showed that MUC5AC only had a tendency to increase and the others did not (Investigative Ophthalmology and Visual Science, 2014, 55(10), 6565˜6574). These results suggested that the pharmacological effects of recoflavone could improve only a part of the symptoms of dry eye and the development potential to an efficient therapeutic agent could be restricted when it was considered that dry eye disease has various symptoms caused by various factors.
In the process of developing a formulation containing recoflavone as a therapeutic agent of dry eye disease, it was confirmed that it was difficult to effectively improve the overall symptoms of dry eye in in vivo studies with a low drug concentration in a simply dissolved state. It was found through the present invention that the overall symptoms of dry eye could be effectively improved just when recoflavone could permeate into tissues and cells in vivo in a certain amount or more. Then it could be developed as a practical therapeutic agent of dry eye disease. Therefore, in the present invention, it is necessary to develop a recoflavone-containing formulation and a method for preparing the same that can efficiently penetrate the cornea to improve the overall symptoms of dry eye significantly in tissues and cells of the eye.
The present invention provides an ophthalmic composition containing recoflavone which efficiently penetrates into the keratoconjunctiva to exhibit significant improvement of the symptoms of dry eye in tissues and cells of the eye. Specifically, the present invention provides an ophthalmic composition wherein:
In addition, the present invention provides an ophthalmic composition for the treatment of dry eye disease, in which the active ingredient, recoflavone, can be dissolved transparently. Specifically, the present invention provides an ophthalmic composition, comprising:
In addition, the present invention provides a method for preparing an ophthalmic composition containing recoflavone which efficiently penetrates into the keratoconjunctiva to exhibit significant improvement of the symptoms of dry eye in tissues and cells of the eye. Specifically, the method comprises:
In addition, the present invention provides an ophthalmic composition maintaining pH stability. Specifically, the present invention provides an ophthalmic composition, comprising:
In addition, the present invention provides the method for administration (usage) of an ophthalmic composition. Specifically, the present invention provides an ophthalmic composition, comprising:
The present invention can effectively improve the symptoms of dry eye disease by increasing the amount of keratoconjunctival permeation in vivo of a recoflavone-containing ophthalmic composition for the treatment of dry eye disease. In particular, the present invention provides a practical and efficient ophthalmic composition for the treatment of dry eye disease by confirming the efficacy of the ophthalmic composition of this invention was superior to that of placebo in a clinical study as well as by improving the overall signs of dry eye disease, such as tear secretion, corneal fluorescence staining score, the detachment of corneal epithelial cells, corneal surface irregularity, conjunctival goblet cell density and mucin cell density.
In addition, a commercially applicable composition and a method for preparing the same are provided for a transparent ophthalmic composition containing 5% (w/v) or more of recoflavone or a pharmaceutically acceptable salt thereof, a hydrate, anhydride or solvate thereof. Surprisingly, the present invention also provides the stable pH of the ophthalmic composition without a buffering agent under long term storage condition (25° C./60% RH), if necessary.
The effects of the present invention are not limited to the abovementioned effects, and various effects may be included within the range that is obvious to those skilled in the art from the description below.
Hereinafter, the present specification will be described in more detail.
Each description and embodiment disclosed in the present invention may be applied to other descriptions and embodiments for each. In other words, all combinations of the various elements disclosed herein fall within the scope of the present invention. In addition, it cannot be considered that the scope of the present invention is limited by the specific descriptions described below.
The inventors of the present invention figured out in the process of developing a formulation containing recoflavone into a therapeutic agent of dry eye disease that it is difficult to effectively improve the overall symptoms of dry eye in in vivo studies with a low drug concentration in a just dissolved state. During the research to develop recoflavone as an effective therapeutic agent of dry eye disease, it was found that when the formulation contains 5% (w/v) or more of recoflavone and 0.1 to 5.0% (w/v) of a permeation enhancer, the amount of keratoconjunctival permeation in vivo is increased to effectively improve the symptoms of dry eye. In addition, the inventors of the present invention completed a commercially applicable composition and a method for preparing the same for a transparent ophthalmic composition containing 5% (w/v) or more of recoflavone or a pharmaceutically acceptable salt thereof, a hydrate, anhydride or solvate thereof. Surprisingly, the present invention also provides the stable pH of the ophthalmic composition containing 5% (w/v) or more of recoflavone or a pharmaceutically acceptable salt thereof, a hydrate, anhydride or solvate without a buffering agent under long term storage condition (25° C./60% RH), if necessary.
Hereinafter, the present specification will be described in more detail.
As used here in the present specification, containing 5% (w/v) or more of recoflavone or a pharmaceutically acceptable salt thereof, a hydrate, anhydride or solvate thereof means containing 5% (w/v) or more as recoflavone, referring to the concentration contained as recoflavone for both the content described as an example and the content that is similar to the description. In addition, the concentration of recoflavone also refers to the concentration as recoflavone.
The ophthalmic composition of the present invention comprises 5% (w/v) or more of recoflavone or a pharmaceutically acceptable salt thereof, a hydrate, anhydride or solvate thereof, and permeation enhancers and tonicity agents. This ophthalmic composition may optionally further comprise viscosity agents, buffering agents, pH-adjusting agents and preservatives.
Specifically, the present invention provides an ophthalmic composition for treating dry eye disease, the composition comprising 5% (w/v) or more of recoflavone or a pharmaceutically acceptable salt thereof, a hydrate, anhydride or solvate thereof; 0.1 to 5.0% (w/v) of permeation enhancers; and 0.01 to 1.0% (w/v) of tonicity agents.
Recoflavone as the active ingredient of the present invention may be used in the form of an anhydride or a solvate including hydrates, and may also be used as one of its pharmaceutically acceptable salt.
In the present invention, recoflavone may be prepared directly by a conventionally known manufacturing method, or may be prepared by commercial purchase.
In the present invention, the term “recoflavone” refers to a 3′,4′,5-trimethoxyflavone derivative compound having the structure of Chemical formula 1 below.
Korean Patent Registration No. 10-0644928 discloses that recoflavone has hygroscopicity in the form of an anhydride as represented by the chemical formula itself, but it is stable without hygroscopicity when it is present in the form of a hydrate, and that it may be present in various solvates. Therefore, it is preferable to use solvates including hydrates in solid dosage forms such as tablet and capsule in the aspect of stability, but in liquid dosage forms such as eye drop, various forms of recoflavone such as anhydrides, solvates including hydrates and its pharmaceutically acceptable salts can be available.
With regard to the concentration of recoflavone, Korean Patent Registration No. 10-0930467 and the prior arts implemented 1 to 3% (w/v) as an active ingredient. However, it was found in the present invention that a certain amount or more of recoflavone must penetrate the tissue in vivo in order to improve significantly overall symptoms of dry eye and, in this case, the concentration of recoflavone should be 5% (w/v) or more in a formulation.
Preferably, the concentration of recoflavone is 5% (w/v) or more and 10% (w/v) or less. More than 10% (w/v) of recoflavone is difficult to apply to an eye drop formulation due to osmolarity.
In the present invention, the “permeation enhancer” refers what plays a role of permeating a certain amount or more of recoflavone in the cornea in vivo so as to improve significantly overall symptoms of dry eye, when an ophthalmic composition containing recoflavone is administered to the eye, and it may be a kind of surfactant that plays a role of enhancing the cell membrane permeation of recoflavone.
The permeation enhancer may be at least one selected from polysorbate, polyoxyethylene alkyl ether, macrogol 115 hydroxystearate, polyoxyl glyceride, tocopheryl polyethylene glycol succinate, poloxamer and polyoxyethylene castor oil derivatives. Specifically, it may be polysorbate 80, polyoxyl 10 oleyl ether, solutol HS15, lauroyl polyoxyl glyceride, vitamin E-TPGS, poloxamer 407 and polyoxyl 35 castor oil.
In the present invention, the permeation enhancer may be used alone or in combination, and when included alone or in combination, it may be included in a range of 0.1 to 5.0% (w/v) in the ophthalmic composition.
In the present invention, a tonicity agent that is commonly used for isotonicity with tear may be used. For example, nonionic compounds such as mannitol, glycerin, propylene glycol, polyethylene glycol, maltose, sucrose, sorbitol, trehalose and glucose or ionic compounds such as sodium chloride, sodium nitrate and potassium nitrate may be used. These tonicity agents may be used alone or in any combination of two or more thereof to adjust osmotic pressure to be similar to that of tear, and may be included in a range of 0.01 to 1.0% (w/v) in the ophthalmic composition.
In the present invention, the ophthalmic composition for treating dry eye disease may optionally further comprise any one or more of viscosity agents, buffering agents, pH-adjusting agents, and preservatives.
Hereinafter, viscosity agents, buffering agents, pH-adjusting agents, and preservatives are described.
In the present invention, a viscosity agent that is commonly used for eye drops may be optionally used, if necessary. For example, nonionic polymers such as polyvinylpyrrolidone, polyvinyl alcohol, hydroxypropylmethylcellulose, hydroxyethylcellulose, methylcellulose; ionic polymers such as sodium carboxymethylcellulose, polycarbophil, carbomer; sugars such as glucan, chitosan, trehalose; and gums such as xanthan gum may be used, and may be optionally comprised in a range of 0 to 3.0% (w/v) in the ophthalmic composition.
As a buffering agent, phosphate, citrate, acetate, hydrogen carbonate, carbonate, gluconate, lactate, propionate, TRIS or borate may be used. In this case, buffering agents may be included in a range of 0 to 3.0% (w/v) in the ophthalmic composition, and these may be used alone or in any combination of two or more.
Buffering agents are generally included to obtain stable physicochemical properties, particularly pH, in most ophthalmic compositions for the shelf life of finished products. However, it has been reported in recent studies that, though borate, phosphate, citrate, or TRIS buffers were commonly used for eye drops, they could be toxic when the high concentration of them were exposed to the human corneal-limbal epithelial cells and human conjunctival epithelial cells (Cornea, 2017, 36(6), 712˜718). It has been also reported that hyaluronate eye drops comprising a phosphate buffer could induce burning or corneal calcification at corneal wounds (Br. J. Ophthalmol. 2010, 94, 1519-1522).
Therefore, if the pH stability of an eye drop can be secured without a buffering agent, it may be desirable to exclude it. In the case of the ophthalmic composition from the present invention containing 5% (w/v) or more of recoflavone or a pharmaceutically acceptable salt thereof, a hydrate, anhydride or solvate thereof, it was surprisingly found that the pH of the ophthalmic composition without a buffering agent kept stable during the shelf-life. On the other hand, it was also found that the pH of the placebo composition without recoflavone or a pharmaceutically acceptable salt thereof, a hydrate, anhydride or solvate thereof, was decreased continuously.
In the present invention, a pH adjusting-agent that is commonly used for eye drops may be used to adjust and maintain the pH in a range that does not irritate or damage the cornea or conjunctiva. As a pH-adjusting agent, conventional acids such as hydrochloric acid, lactic acid, acetic acid, phosphoric acid, boric acid and citric acid or conventional bases such as sodium hydroxide, potassium hydroxide may be used alone or in any combination of two or more thereof. In this case, the pH adjusting agent and the amount of the same in the ophthalmic formulation may be optionally included so that the pH may be in a range from 4 to 8, or the amount of the pH adjusting agent may be set during the preparation of the composition preferably in a pH range from 5 to 7. The pH adjusting agent may be included in a range of 0.01 to 3.0% (w/v) in the ophthalmic composition.
In the present invention, for the purpose of preventing the eye drop from contamination with bacteria or fungi, a preservative that is commonly used in eye drops may be optionally used, if necessary, and it usually depends on whether a multi-use container or a disposable container is used as a package of an ophthalmic formulation. For example, tertiary ammonium salts such as benzalkonium chloride and benzethonium chloride; paraoxybenzoic acid esters such as methylparaben and propylparaben; alcohols such as chlorobutanol and benzyl alcohol; chlorhexidine acetate and sodium edetate may be used alone or in any combination of two or more thereof, and may be optionally included in a range of 0 to 0.1% (w/v) in the ophthalmic composition.
In the present invention, the ophthalmic composition for the treatment dry eye disease may not comprise a viscosity agent, a buffering agent and/or a preservative, and if not comprised, the lower limit of the content of each ingredient can be expressed as 0% (w/v). In other words, in the present invention, the meaning of 0% (w/v) is that the ingredients may be optionally used, if necessary.
In the present invention, for the ophthalmic composition for the treatment of dry eye disease, the cumulative permeation amount of recoflavone in the cornea of minipig for 6 hours is 130 μg/cm2 or more, or 3 times or more compared to an ophthalmic composition that does not contain a permeation enhancer. In this case, the cumulative permeation amount of recoflavone means the total amount of recoflavone that has permeated the cornea of minipig for 6 hours when tested according to Experimental Example 1.
Because the cornea has a function of protecting the eyes and acts as a barrier to drug absorption, it is necessary to secure an appropriate corneal permeation amount of drug to successfully develop an eye drop.
Recoflavone has the advantage of being able to prepare an eye drop in a fully transparent solution through the preparation method of the present invention even at a high concentration of 3% (w/v) or 5% (w/v). However, the eye drops containing recoflavone that is just dissolved at a high concentration failed to show a significant improvement of the overall symptoms of dry eye disease in in vivo studies, and the results of the corneal permeability test confirmed that recoflavone could not penetrate in a sufficient amount although recoflavone was dissolved at a high concentration. In the present invention, it was confirmed that the corneal permeation amount of recoflavone was significantly increased when a permeation enhancer was included in the recoflavone-containing ophthalmic composition, which induced the superior efficacy of the ophthalmic composition of this invention to that of placebo in a clinical study as well as the improvement of the overall signs of dry eye disease in the experimental dry eye animal model.
In this case, the details mentioned about the ophthalmic composition for the treatment of dry eye disease and the improvement of the permeation of the ophthalmic composition are equally applied as long as they do not contradict each other. The description about the ophthalmic composition for the treatment of dry eye disease can all be applied to the improvement of the permeation of the ophthalmic composition.
In addition, the present invention provides an ophthalmic composition for the treatment of dry eye disease in which the active ingredient, recoflavone, can be transparently dissolved.
Specifically, the present invention provides an ophthalmic composition for the treatment of dry eye disease, comprising:
In the present invention, the alkalizing agent is sodium hydroxide or potassium hydroxide.
Details about this will be described in the preparation method of the ophthalmic composition for the treatment of dry eye disease.
In this case, the details mentioned about the ophthalmic composition for the treatment of dry eye disease and the ophthalmic composition in which the content of an alkalizing agent is adjusted are equally applied as long as they do not contradict each other. The description about the ophthalmic composition for the treatment of dry eye disease can all be applied to the ophthalmic composition in which the content of an alkalizing agent is adjusted.
In addition, the present invention provides a method for preparing an ophthalmic composition for the treatment of dry eye disease that can exhibit effective improvement of the symptoms of dry eye.
Specifically, the method comprises: (S1) adding and dissolving recoflavone, a hydrate, anhydride or solvate thereof into a solution prepared by adding and dissolving an alkalizing agent into purified water; (S2) adjusting pH to a range from 4 to 8 by adding an acidifying agent to the solution obtained through (S1); (S3) adding and dissolving at least one pharmaceutical additive consisting of a permeation enhancer, a tonicity agent, a buffering agent and a preservative into the solution obtained through (S2); and (S4) filtering the solution obtained through (S3).
In the preparation method of the present invention, recoflavone and a hydrate, anhydride or solvate thereof are referred to as recoflavone.
In general, an ophthalmic composition is preferably prepared in a transparent solution state in consideration of the feeling of use in eyes and the efficient absorption of the drug. However, because recoflavone in the form of a hydrate or others is practically insoluble in water as described above, a specific method is required for preparing a transparent solution. Therefore, if recoflavone is not dissolved in purified water for an ophthalmic composition, a transparent solution may be prepared through (S1) step.
In the present invention, the alkalizing agent for pH adjustment in (S1) step is sodium hydroxide or potassium hydroxide, preferably, sodium hydroxide. In (S2) step, the acidifying agent for pH adjustment may be used by selecting one or more from hydrochloric acid, lactic acid, acetic acid, phosphoric acid, boric acid, and citric acid, preferably, one or more selected from hydrochloric acid, phosphoric acid and acetic acid, and most preferably, hydrochloric acid.
When recoflavone is not dissolved in purified water, in (S1) step, sodium hydroxide as an alkalizing agent is added in an amount of not less than 1.05 which is the ratio of molar concentration to that of recoflavone. Here, the ratio of molar concentration is expressed as a value by dividing the molar concentration of sodium hydroxide by the molar concentration of recoflavone contained in the ophthalmic composition.
Specifically, (S1) step is a process where sodium hydroxide is added to purified water to prepare an aqueous solution having a molar concentration of not more than 0.16 M or not less than 0.19 M, and then recoflavone is added. Recoflavone can be dissolved transparently through the above process.
The molar concentration of sodium hydroxide is calculated in the above dissolving process not in the final volume of the manufacturing process. Surprisingly, when recoflavone was added in an aqueous solution of sodium hydroxide having a molar concentration out of the range of not more than 0.16 M or not less than 0.19 M, recoflavone was not dissolved transparently even after stirring for several hours. Therefore an ophthalmic composition cannot be prepared efficiently. The corresponding contents will be described in details with reference to Tables 1, 2 and
In this case, the amount of an alkalizing agent, particularly sodium hydroxide, may be adjusted within the available range in consideration of the osmolarity of an ophthalmic composition and so the ratio of molar concentration by 2.0 or higher is not 10 used.
In case of the ophthalmic composition containing 7% (w/v) or more of recoflavone with the ratio of molar concentration of sodium hydroxide by not less than 1.05, a clear dissolution of the active ingredient is not difficult to prepare because the molar concentration of sodium hydroxide is in the range of not less than 0.19M even though total volume of purified water is applied.
In case of the ophthalmic composition containing 3% (w/v) recoflavone, it is not also difficult to obtain a clear dissolution of the active ingredient which corresponds to the opposite case.
However, in case of the ophthalmic composition containing 5% (w/v) or 6% (w/v) recoflavone, the molar concentration of the sodium hydroxide aqueous solution may be out of the range of not more than 0.16 M or not less than 0.19 M depending on the applied amount of purified water first in the process. Unexpectedly, if recoflavone is not dissolved clearly due to out of the above range at this time, even though purified water is added again to adjust the molar concentration to not more than 0.16 M, it is too difficult to obtain a clear solution of recoflavone even after stirring for several hours. This would cause a big trouble in the manufacturing process of an eye drop.
In the present invention, in (S1) step, recoflavone, a hydrate, anhydride, or solvate thereof may be dissolved transparently in the ophthalmic composition in an amount of 5% (w/v) or more as recoflavone and specifically it may be dissolved transparently in the ophthalmic composition in an amount of 5% to 10% (w/v) as recoflavone.
In the present invention, the pH-adjusting agent used in (S2) step may be an acidifying agent. Specifically, when an alkalizing agent is used for dissolving recoflavone in (S1) step, the pH of the solution is increased to 10 or higher. Therefore, in (S2) step, an acidifying agent is added to adjust the pH to be in a range of 4 to 8 in consideration of the properties of an eye drop administered directly to eyes and the physicochemical properties of recoflavone.
In the present invention, in (S3) step, when one or more pharmaceutical additives are added, a permeation enhancer may be added to be 0.1 to 5.0% (w/v) in the ophthalmic composition, a tonicity agent to be 0.01 to 1.0% (w/v) in the ophthalmic composition, and a pH-adjusting agent to be 0.01 to 3.0% (w/v) in the ophthalmic composition. In this case, specifically the pH-adjusting agent comprises 0.01 to 2.5% (w/v) of an alkalizing agent and 0.001 to 0.5% (w/v) of an acidifying agent.
In the present invention, in (S3) step, when one or more pharmaceutical additives are added, a buffering agent may be added to be 0 to 3.0% (w/v) in the ophthalmic composition, and a preservative is to be 0 to 0.1% (w/v) in the ophthalmic composition.
In the present invention, the permeation enhancer may be one or more selected from polysorbate, polyoxyethylene alkyl ether, macrogol 15 hydroxystearate, polyoxyl glyceride, tocopheryl polyethylene glycol succinate, poloxamer and polyoxyethylene castor oil derivative, and specifically, one or more selected from polysorbate 80, polyoxyl 10 oleyl ether, solutol HS15, lauroyl polyoxyl glyceride, vitamin E-TPGS, poloxamer 407 and polyoxyl 35 castor oil.
In the present invention, the tonicity agent may be one or more selected from nonionic compounds consisting of mannitol, glycerin, propylene glycol, polyethylene glycol, maltose, sucrose, sorbitol, trehalose and glucose or ionic compounds consisting of sodium chloride, sodium nitrate and potassium nitrate.
In the present invention, a step of mixing by adding a viscosity agent to the solution obtained through the (S3) step may be further included before the (S4). This is not an essential step, and 0 to 3.0% (w/v) of a viscosity agent may be added and mixed.
In the present invention, before the (S4) step, the process of adding purified water to the solution obtained through (S3) step and checking the pH in the range of 4 to 8 may be further included.
Specifically, after checking the pH in the range of 4 to 8, a pH-adjusting agent may be added to adjust, if necessary.
The details mentioned about the ophthalmic composition for the treatment of dry eye disease, the ophthalmic composition in which the content of an alkalizing agent is adjusted, and the method for preparing the ophthalmic composition for the treatment of dry eye disease according to the present invention are equally applied as long as they do not contradict each other. The description about the ophthalmic composition for the treatment of dry eye disease and the ophthalmic composition in which the content of an alkalizing agent is adjusted can all be applied to the method for preparing the ophthalmic composition for the treatment of dry eye disease.
In addition, the present invention provides an ophthalmic composition which provides the pH stability even without a buffering agent, if necessary.
Specifically, the present invention provides an ophthalmic composition for the treatment of dry eye disease, the composition containing 5% (w/v) or more of recoflavone or a pharmaceutically acceptable salt thereof, a hydrate, anhydride or solvate thereof,
In the present invention, the alkalizing agent is sodium hydroxide or potassium hydroxide.
In the present invention, the acidifying agent is one or more selected from the group of hydrochloric acid, lactic acid, acetic acid, phosphoric acid, boric acid and citric acid.
In the present invention, the ophthalmic composition which provides the pH stability maintains the pH in a range of 4 to 8 under long-term storage conditions (25° C./60% RH), specifically, the pH in a range of 5 to 7.
Specifically, the pH stability was confirmed since the pH was maintained in the range of 4 to 8, specifically 5 to 7, for 18 months under long-term storage conditions (25° C./60% RH)
The details mentioned about the ophthalmic composition for the treatment of dry eye disease and the ophthalmic composition which provides the pH stability are equally applied as long as they do not contradict each other. The description about the ophthalmic composition for the treatment of dry eye disease can all be applied to the ophthalmic composition which provides the pH stability.
In addition, the present invention provides a method for the administration of an ophthalmic composition.
Specifically, the present invention provides an ophthalmic composition for the treatment of dry eye disease, the composition containing 5% (w/v) or more of recoflavone or a pharmaceutically acceptable salt thereof, a hydrate, anhydride or solvate thereof; and
For the ophthalmic composition of the present invention, it is advantageous that the active ingredient is sufficiently exposed to the eyes so that the drug can be delivered to the inside or outside of the keratoconjunctival cells of the eye in a certain amount or more for significant improvement of the overall symptoms of dry eye. Therefore, the method for the administration of the ophthalmic composition of the present invention is preferable to instill 1 to 2 drops at a time, 3 times or more a day.
Specifically, 1 drop at a time may be instilled 3 times or more, 4 times or more, 5 times or more, or 6 times or more, and more specifically, 1 drop at a time may be instilled 3 to 6 times.
In the present invention, the permeation enhancer may be one or more selected from polysorbate, polyoxyethylene alkyl ether, macrogol 15 hydroxystearate, polyoxyl glyceride, tocopheryl polyethylene glycol succinate, poloxamer and polyoxyethylene castor oil derivative, and specifically, one or more selected from polysorbate 80, polyoxyl 10 oleyl ether, solutol HS15, lauroyl polyoxyl glyceride, vitamin E-TPGS, poloxamer 407 and polyoxyl 35 castor oil.
In the present invention, the concentration of recoflavone is preferably not less than 5% (w/v) and not more than 10% (w/v). More than 10% (w/v) of recoflavone causes many difficulties involved in physical properties such as the osmolarity of an eye drop and practical problems such as the cost of products.
The ophthalmic composition according to the present invention may be administered in combination with other eye drops, and in this case, may be administered at an interval of at least 5 minutes.
The details mentioned about the ophthalmic composition for the treatment of dry eye disease and the usage of the ophthalmic composition are equally applied as long as they do not contradict each other. The description about the ophthalmic composition for the treatment of dry eye disease can all be applied to the usage of the ophthalmic composition.
Hereinafter, preferred Examples are presented to help the understanding of the present invention. However, the following Examples are provided for easier understanding of the present invention, and the content of the present invention is not limited by the Examples.
An ophthalmic composition was prepared according to the ratio shown in Table 3 below. While stirring an appropriate amount of purified water, sodium hydroxide was added to the purified water to dissolve, and then recoflavone monohydrate was added to dissolve transparently. After the dissolution, hydrochloric acid was added to the dissolved solution to adjust to pH 4 to 8, and then a permeation enhancer, a tonicity agent, a buffering agent and a preservative were added to dissolve. A viscosity agent was separately put into in an appropriate amount of purified water and dissolved by heating or by keeping at room temperature depending on the type, and then added to the solution described above and mixed. However, the input order of a preservative, a permeation enhancer, a viscosity agent and a tonicity agent may be changed depending on the type and amount thereof. A viscosity agent, a buffering agent and a preservative may be omitted, if necessary. After checking if the pH was 4 to 8, the pH was adjusted using a pH-adjusting agent, if necessary. Additional purified water was applied to make sure the correct volume. The solution was passed through a filter of 0.22 μm or less to prepare a transparent ophthalmic composition.
In order to evaluate the degree of permeation of the ophthalmic composition in the keratoconjunctiva, the permeation rate was measured by using the cornea of minipig which is relatively uneasy to permeate and which allows for a corneal permeation test. In general, it is reported that the conjunctiva is 2-3 times easier to permeate compared to the cornea.
The in vitro test of corneal permeation for the ophthalmic compositions according to Comparative Examples and Examples was conducted by using a vertical Franz diffusion cell device. The cornea with the surrounding sclera for test was harvested from the eyes of minipigs that weighed 40 to 50 kg. In order to fix the cornea in Franz diffusion cell, the corneal region was only exposed at the center of receptor chamber. Then, the donor chamber was covered and fixed with a joint. Cautions were taken to remove the air from the area where the receptor chamber meets the cornea. 5 mL of phosphate solution (PBS buffer) at pH 7.4 and a magnetic stirrer were put into the receptor chamber. 1mL of test solution was put into the donor chamber, which was then closed with a lid and sealed with a parafilm. During the permeability test, the stirrer kept at about 500 rpm, and the Franz diffusion cells kept at 36.5° C. At 0.5, 1, 2, 4 and 6 hours, 200 μL of each sample was taken and the same amount of phosphate solution (PBS buffer) was supplemented. The drug concentration in the collected samples was measured by using an HPLC analysis instrument. The concentration measured in each sample was converted to the permeation amount per time, and the amount of the diluent was corrected to calculate the cumulative permeation amount of recoflavone for 6 hours. The results of in vitro permeability test by using the cornea of minipig confirmed that the permeation enhancer which was contained in Examples increased the cumulative permeation amount of recoflavone.
The cumulative permeation amount per unit area in each individual sample was plotted with the average over sampling time, and the linear regression analysis was performed. The slope of equation was calculated as the average permeation rate (flux) of the drug for 6 hours. The relative permeation enhancement ratio was calculated as the ratio of the average permeation rate for 6 hours of each Example compared to Comparative Example 1 (see equation 1).
Through the above method, the average cumulative permeation amount and the average permeation rate over time per unit area of the cornea, and the relative permeation enhancement ratio of the ophthalmic compositions of Examples 1 to 3 and Comparative Examples 1 and 2 were calculated and are shown in Table 4.
Referring to Table 4, Examples 1 to 3 confirmed that permeation of the drug was different depending on the presence or absence of a permeation enhancer at the same drug concentration compared to Comparative Example 1 which contains only the active ingredient like a conventional eye drop composition. In addition, Example 1 confirmed that the permeation was enhanced depending on the concentration of recoflavone at the same composition compared to Comparative Example 2.
In addition, it was confirmed that the permeability of Comparative Example 2 which had a lower concentration of recoflavone but had a permeation enhancer was higher than that of Comparative Examples 1.
The results showed that Example 1 had an average permeation rate of 27 μg/cm2/hr for 6 hours and so the relative permeation enhancement ratio increased 3.4 times compared to Comparative Example 1 without a permeation enhancer.
The improvement of the symptoms of dry eye in vivo was also comparatively evaluated in Experimental Examples described below, and the results showed that the overall improvement by Example 1 was significantly better than those by Comparative Example 1 without a permeation enhancer.
Therefore, in pursuit of the overall improvement of the symptoms of dry eye in vivo rather than simply getting better the laboratory data, it was confirmed that the relative permeation enhancement ratio for 6 hours in the cornea of minipig, compared to Comparative Example 1 without a permeation enhancer, should preferably be 3.0 or higher, or the cumulative permeation amount should preferably be 130 μg/cm2 or more.
It was evaluated the effect of the improved corneal permeation of the ophthalmic composition on the tear secretion in the experimental dry eye mouse model.
NOD.B10.H2b mice 12 to 14 weeks old (Jackson Laboratory, Bar Harbor, USA) were adapted for 7 days and were injected subcutaneously with 0.5 mg/0.2 mL scopolamine hydrobromide into hindquarters 4 times daily (8 am, 11 am, 2 pm, 5 pm) for 10 days with desiccation stress at below average 40% of ambient humidity. After checking the occurrence of dry eyes, the placebo (the composition without the active ingredient in Example 1), Comparative Example 1 and Example 1 were each instilled into both eyes at a dose of 5 μL, four times a day for 21 days.
To measure the tear volume, phenol red-impregnated cotton threads were placed in the lateral canthus for 20 seconds. The lengths of the thread in which tear was absorbed were converted into microliters (μL).
It was evaluated the effect of the improved corneal permeation of the ophthalmic composition on the corneal fluorescence staining (CFS) in the experimental dry eye mouse model.
On the same condition of Experimental Example 2, Comparative Example 3, Comparative Example 1 and Example 1 were instilled for 10 days and 1 μL of 1% fluorescein reagent was applied into the eyes to stain the cornea and the eyes was washed with saline. Images were taken with a digital slit lamp to score and evaluate the degree of epithelial damage (the degree of fluorescence staining). The scores from 1 to 3 points for each five areas of cornea were given and added up.
It was evaluated the effect of the improved corneal permeation of the ophthalmic composition on the corneal surface irregularity in the experimental dry eye mouse model.
On the same conditions of experimental Example 2, Comparative Example 3, Comparative Example 1 and Example 1 were instilled for 10 days. The white ring images of the cornea surface were reflected and acquired from the fiber optic ring illuminator of a stereoscopic microscope (SZX7, Olympus). The corneal surface irregularity score was given in the reflected ring: 0 point no distortion; 1 point, distortion in 1 quarter of the ring; 2 points, distortion in 2 quarters; 3 points, distortion in 3 quarters; 4 points, distortion in all 4 quarters; 5 points, severe distortion.
The corneal surface irregularity was evaluated to check the effect on the corneal curing by the method described above (
It was evaluated the effect of the improved corneal permeation of the ophthalmic composition on the detachment of corneal epithelial cell in the experimental dry eye mouse model.
On the same conditions of Experimental Example 2, Comparative Example 3, Comparative Example 1 and Example 1 were instilled for 21 days and the animals were sacrificed.
The surgically excised periocular region and lacrimal gland were fixed in 10% formalin for 3 days and embedded in paraffin. The 5 μm tissue was cut with a microtome and dried for 1 hour on a slide. The tissue was prepared by the Hematoxylin-Eosin (H&E) staining method and the detached epithelial cell was evaluated in the 1 mm2 of corneal region by a virtual microscope (Nanozoomer 2.0RS, Hamamatsu, Japan). In order to compare exactly the degree of improvement of the symptoms of dry eye, the eye tissue at the time right before the drug administration after dry eye was fully induced (initial) and the eye tissue of the normal mouse that was exposed to neither the drug or nor the dry environment stress for 10 days (normal eye) were compared together.
It was evaluated the effect of the improved corneal permeation of the ophthalmic composition on the density of goblet cells for the mucus secretion in the experimental dry eye mouse model.
On the same conditions of Experimental Example 5, the paraffin-embedded tissue was sectioned and put on a slide. The staining was performed according to the instructions of the PAS (Periodic-Acid-Schiff) kit and the density of goblet cells was evaluated in the 1 mm2 of conjunctival region by a virtual microscope (Nanozoomer 2.0RS, Hamamatsu, Japan).
It was evaluated the effect of the improved corneal permeation of the ophthalmic composition on the distribution of mucins, a major component of mucus, in the experimental dry eye mouse model.
On the same conditions of Experimental Example 5, the paraffin-embedded tissue was sectioned and put on a slide. The staining was performed according to the instructions of the Alcian Blue Stain kit and it was evaluated in the 1 mm2 of corneal and conjunctival regions by a virtual microscope (Nanozoomer 2.0RS, Hamamatsu, Japan).
It was evaluated the clinical efficacy and safety of the ophthalmic composition containing 5% (w/v) of recoflavone (Example 5) in patients with dry eye disease within the inclusion criteria. It was a multi-center, randomized, double-blind, placebo-controlled, phase 2 clinical study. Specifically, a run-in period was employed after screening patients who are within the inclusion criteria of this clinical study. The patients who kept an acceptable level of medical compliance were randomized into three groups (placebo group, test 3 times-a-day group, and test 6 times-a-day group). Thirty-three subjects were assigned to each group. The efficacy and safety were evaluated by administering 1 drop, 3 times or 6 times a day, for up to 12 weeks. The change of the total corneal staining score (TCSS) from the baseline was measured by fluorescein for the efficacy evaluation. In addition, adverse events, vital signs, laboratory tests, electrocardiogramand ophthalmic tests were performed to evaluate the safety at each visit.
Table 5 and
Based on the results of the clinical study above, the novel recoflavone-containing ophthalmic composition containing a permeation enhancer in the present invention was evaluated to show a practical and significant improvement of dry eye disease in human, which could not be overcome by the conventional inventions.
The pH of the ophthalmic solutions of Example 5 and the placebo were evaluated under long-term storage conditions (25° C./60% RH) and the results are shown in
In spite of no buffering agent in Example 5, the pH was stable within the range of 6 to 7, which was the initial pH, for 18 months under long-term storage conditions, whereas the pH of the placebo containing no recoflavone showed a continuous decline.
A buffering agent has been used in most eye drops to maintain stable physicochemical properties, especially pH, during the shelf life of products. Recently, it was suggested that a buffering agent could cause some problems. Surprisingly, it was confirmed that the ophthalmic compositions of the present invention can keep the pH stable under long-term storage conditions (25° C./60% RH) even though the composition does not contain a buffering agent, if necessary.
As shown above, a specific part of the present invention was described in details, and for those of ordinary skill in the related art, this specific technology is only a preferred embodiment, and it is clear that the scope of the present invention is not limited thereto. Therefore, the substantial scope of the invention will be defined by the appended claims and their equivalents.
| Number | Date | Country | Kind |
|---|---|---|---|
| 10-2021-0103200 | Aug 2021 | KR | national |
| 10-2022-0097206 | Aug 2022 | KR | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/KR2022/011567 | 8/4/2022 | WO |
